Bryant Furlow

Contributing Writer https://www.cancertherapyadvisor.com

Bryant Furlow is a contract medical journalist for the Haymarket Medical Network. He holds a bachelor of science in biology (summa cum laude) from the University of New Mexico. He covers radiation oncology, immunotherapy, tumor biology, clinical research, and health care policy. Prior to becoming a contributor to Haymarket Media in 2010, Bryant was a newspaper reporter in New Mexico, where he won awards for public health and investigative journalism. He also reports for The Lancet Oncology news desk.

All articles by Bryant Furlow

The Leukemia & Lymphoma Society partnered with Sutro Biopharma to test the safety of the investigati

ESMO 2019

Blood Test May Potentially Replace Invasive Biopsy for Certain Patients With Lung Cancer: Results of BFAST

Bryant Furlow

October 1, 2019

Liquid biopsy can be used to detect a complex type of driver mutation, called ALK, in patients with NSCLC.

ESMO 2019

Pembrolizumab Does Not Outperform Chemotherapy in Mesothelioma

Bryant Furlow

September 30, 2019

While pembrolizumab was not superior to chemotherapy, survival times were similar, suggesting immunotherapy might offer an alternative to chemotherapy.

Patients with breast cancer report financial barriers to quality care and provide suggestions for alleviating the economic burdens of the disease.

ESMO 2019

Palbociclib, Capecitabine Regimens Offer Similar Patient-Reported Quality-of-Life Outcomes in Metastatic HR-Positive Breast Cancer

Bryant Furlow

September 30, 2019

Results of the YoungPearl study revealed that patient-reported QoL scores were high for palbociclib plus endocrine therapy.

Trastuzumab emtansine reduces the risk of recurrence by 50% in some HER2-positive breast cancers following neoadjuvant chemotherapy.

ESMO 2019

Abemaciclib Plus Fulvestrant Improved Survival in Patients with HR+, HER2- Advanced Breast Cancer

Bryant Furlow

September 30, 2019

Results of MONARCH-2 showed a statistically significant and clinically meaningful improvement in overall survival with abemaciclib plus fulvestrant.

ESMO 2019

Pembrolizumab Does Not Prolong Survival Compared With Chemotherapy in Metastatic TNBC

Bryant Furlow

September 29, 2019

Pembrolizumab monotherapy does not improve overall survival (OS) compared with single-agent chemotherapy among women with metastatic triple negative breast cancer (mTNBC).

ESMO 2019

Adjuvant Sorafenib Does Not Improve Survival in Renal Cell Carcinoma

Bryant Furlow

September 29, 2019

Active surveillance remains the standard of care for patients at intermediate or high risk of recurrence following nephrectomy.

Findings from the SPARTAN trial show that HRQoL is not diminished by adding apalutamide to androgen

ESMO 2019

First-Line Combination Immunotherapy Deemed Superior to Chemotherapy in Advanced Lung Cancer

Bryant Furlow

September 29, 2019

“In my opinion, these data are practice changing,” said lead study author Solange Peters.

Afatinib may demonstrate clinical activity in patients with EGFR mutation-positive non-small cell lu

ESMO 2019

Biomarkers May Predict Immune Checkpoint Blockade-Related Hyperprogression in Lung Cancer

Bryant Furlow

September 28, 2019

Nearly 11% of patients in the study who underwent immune checkpoint inhibition for NSCLC experienced HPD.

An Italian trial reported fewer deaths with annual or biennial low-dose CT lung screening—and an active surveillance approach reduced overdiagnosis.

ESMO 2019

Real-World Survival Rates Reported for Nivolumab in Previously Treated NSCLC

Bryant Furlow

September 28, 2019

Nivolumab monotherapy for advanced NSCLC was associated with lower overall survival rates in real-world settings than those seen in clinical trial settings.

Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.

Lymphoma

Implant-Associated Cancers: A Look Beyond BIA-ALCL

Bryant Furlow

September 16, 2019

Recent and upcoming case reports suggest possible cases of gluteal and other implant-associated ALCLs, raising questions about the cancer risk across all types of implants.

Next post in Lymphoma